SCHEMBL17441

SCHEMBL17441

C[Si](C)(C)OCC1OC(=O)C(O[Si](C)(C)C)C(O[Si](C)(C)C)C1O[Si](C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2462698 1.00
SCHEMBL14179775 1.00
SCHEMBL10210919 1.00
SCHEMBL14782740 1.00
SCHEMBL18464513 1.00
SCHEMBL15031196 1.00
SCHEMBL13271938 1.00
SCHEMBL3731733 1.00
SCHEMBL20702230 1.00
SCHEMBL1863374 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016142950-A1 A NOVEL PROCESS FOR PREPARING (2S,3R,4R,5S,6R)-2-{3-[5-[4-FLUORO-PHENYL)- THIOPHEN-2-YLMETHYL]-4-METHYL-PHENYL}-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,4,5- TRIOL AND ITS STABLE AMORPHOUS HEMIHYDRATE FORM HARMAN FINOCHEM LIMITED (IN) 2016-09-15 WO claimed
EP-4739697-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zaklady Farmaceutyczne Polpharma S.A. (PL) 2026-05-13 EP disclosed
WO-2025008539-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN Zakłady Farmaceutyczne POLPHARMA S.A. (PL) 2025-01-09 WO disclosed
CN-111233915-B Preparation method of 2,3,4, 6-tetra-O-trimethylsilyl-D-glucolactone 上海科胜药物研发有限公司 2023-09-22 CN disclosed
EP-4036100-A1 SPIROKETAL DERIVATIVES AND PROCESS FOR PREPARATION OF SPIROKETAL DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-08-03 EP disclosed
EP-3170834-B1 CRYSTALLINE FORMS OF (1S,3'R,4'S,5'S,6'R)-6-[(4-ETHYLPHENYL)METHYL]-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO[ISOBENZOFURAN-1(3H) 2'-[2H]PYRAN]-3',4',5'-TRIOL CHUGAI PHARMACEUTICAL CO LTD (JP) 2022-02-09 EP disclosed
US-11198703-B2 Process for the preparation of SGLT2 inhibitors and intermediates thereof Piramal Enterprises Limited (IN) 2021-12-14 US disclosed
EP-2896397-B2 Novel compounds having inhibitory activity against sodium-dependant glucose transporter MITSUBISHI TANABE PHARMA CORP (JP) 2020-10-07 EP disclosed
CN-111233915-A Preparation method of 2,3,4, 6-tetra-O-trimethylsilyl-D-gluconolactone 上海科胜药物研发有限公司 2020-06-05 CN disclosed
US-20200123186-A1 A PROCESS FOR THE PREPARATION OF SGLT2 INHIBITORS AND INTERMEDIATES THEREOF Piramal Enterprises Limited (IN) 2020-04-23 US disclosed
US-20110306778-A1 CRYSTAL OF SPIROKETAL DERIVATIVES AND PROCESS FOR PREPARATION OF SPIROKETAL DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-12-15 US disclosed
WO-2011107494-A1 NOVEL AROMATIC GLYCOSIDE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND THE USE THEREOF SANOFI (FR) 2011-09-09 WO disclosed
EP-2312944-A1 DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE Theracos, Inc. (US) 2011-04-27 EP disclosed
EP-2308886-A1 CRYSTAL OF SPIROKETAL DERIVATIVE, AND PROCESS FOR PRODUCTION THEREOF Chugai Seiyaku Kabushiki Kaisha (JP) 2011-04-13 EP disclosed
EP-2187742-A1 BENZYLBENZENE DERIVATIVES AND METHODS OF USE Theracos, Inc. (US) 2010-05-26 EP disclosed
US-20100094025-A1 METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF ASTELLAS PHARMA INC. (JP) 2010-04-15 US disclosed
US-20100094025-A1 METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND INTERMEDIATE FOR SYNTHESIS THEREOF ASTELLAS PHARMA INC. (JP) 2010-04-15 US disclosed
WO-2010009243-A1 DEUTERATED BENZYLBENZENE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2010-01-21 WO disclosed
EP-2105442-A1 METHOD FOR PRODUCING C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE THEREOF Astellas Pharma Inc. (JP) 2009-09-30 EP disclosed
WO-2009026537-A1 BENZYLBENZENE DERIVATIVES AND METHODS OF USE THERACOS, INC. (US) 2009-02-26 WO disclosed